• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Management of chronic respiratory diseases during viral pandemics: A concise review of guidance and recommendations.病毒性大流行期间慢性呼吸道疾病的管理:指南与建议简要综述
J Family Med Prim Care. 2022 Nov;11(11):6633-6639. doi: 10.4103/jfmpc.jfmpc_974_21. Epub 2022 Dec 16.
2
Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.重症监护治疗新型冠状病毒 SARS-CoV-2 感染患者:意大利克雷马医院的经验。
Am J Emerg Med. 2021 Jul;45:156-161. doi: 10.1016/j.ajem.2020.08.005. Epub 2020 Aug 16.
3
Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection.关于成人新型冠状病毒肺炎继发急性呼吸衰竭患者无创呼吸支持的临床共识推荐
Med Intensiva (Engl Ed). 2020 Oct;44(7):429-438. doi: 10.1016/j.medin.2020.03.005. Epub 2020 Mar 30.
4
Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.澳大利亚和新西兰 2019 冠状病毒病(COVID-19)危重症和急症住院患者的营养管理。
Aust Crit Care. 2020 Sep;33(5):399-406. doi: 10.1016/j.aucc.2020.06.002. Epub 2020 Jul 2.
5
Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions.新型冠状病毒病 2019 与哮喘、变应性鼻炎:分子机制与宿主-环境相互作用。
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):1-7. doi: 10.1097/ACI.0000000000000699.
6
[Asthma and COPD management during the COVID-19 pandemic].[COVID-19大流行期间的哮喘与慢性阻塞性肺疾病管理]
Rev Med Suisse. 2020 May 6;16(692):933-938.
7
Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.巴西原住民中由严重急性呼吸综合征冠状病毒2感染或其他病原体引起的严重急性呼吸综合征:一项关于冠状病毒病(COVID)-19大流行第一年的观察性研究。
Lancet Reg Health Am. 2022 Apr;8:100177. doi: 10.1016/j.lana.2021.100177. Epub 2022 Jan 7.
8
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究:一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
9
Surgical Infection Society Guidance for Operative and Peri-Operative Care of Adult Patients Infected by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).外科感染学会关于成人严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)感染者手术和围手术期护理的指南。
Surg Infect (Larchmt). 2020 May;21(4):301-308. doi: 10.1089/sur.2020.101. Epub 2020 Apr 20.
10
Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD).严重 COVID-19 与结缔组织病相关间质性肺病(CTD-ILD)急性加重的临床、血清学和组织病理学比较。
Front Immunol. 2020 Oct 2;11:587517. doi: 10.3389/fimmu.2020.587517. eCollection 2020.

引用本文的文献

1
Interplay between Lung Diseases and Viral Infections: A Comprehensive Review.肺部疾病与病毒感染之间的相互作用:综述
Microorganisms. 2024 Oct 8;12(10):2030. doi: 10.3390/microorganisms12102030.

本文引用的文献

1
Does inhaled corticosteroid use affect the risk of 
COVID-19-related death?吸入性糖皮质激素的使用是否会影响与COVID-19相关的死亡风险?
Breathe (Sheff). 2021 Mar;17(1):200275. doi: 10.1183/20734735.0275-2020.
2
Pulmonary function testing during the COVID-19 pandemicin.2019年冠状病毒病大流行期间的肺功能测试
Lung India. 2021 Mar;38(Supplement):S92-S96. doi: 10.4103/lungindia.lungindia_738_20.
3
A Low-Cost, Ear-Contactless Electronic Stethoscope Powered by Raspberry Pi for Auscultation of Patients With COVID-19: Prototype Development and Feasibility Study.一种由树莓派驱动的低成本、非耳部接触式电子听诊器,用于新冠肺炎患者听诊:原型开发与可行性研究
JMIR Med Inform. 2021 Jan 19;9(1):e22753. doi: 10.2196/22753.
4
Asthma and COVID-19: a systematic review.哮喘与2019冠状病毒病:一项系统综述
Allergy Asthma Clin Immunol. 2021 Jan 6;17(1):5. doi: 10.1186/s13223-020-00509-y.
5
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.吸入性类固醇 Ciclesonide 通过靶向细胞培养中的病毒复制转录复合物来阻断 SARS-CoV-2 RNA 复制。
J Virol. 2020 Dec 9;95(1). doi: 10.1128/JVI.01648-20.
6
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.间质性肺疾病患者 COVID-19 住院治疗结局。一项国际多中心研究。
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1656-1665. doi: 10.1164/rccm.202007-2794OC.
7
The association between COVID-19 and asthma: A systematic review and meta-analysis.2019冠状病毒病与哮喘之间的关联:一项系统评价和荟萃分析。
Clin Exp Allergy. 2020 Nov;50(11):1274-1277. doi: 10.1111/cea.13733. Epub 2020 Sep 24.
8
Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19.慢性阻塞性肺疾病和吸烟对 COVID-19 结局的影响。
Int J Tuberc Lung Dis. 2020 Aug 1;24(8):838-843. doi: 10.5588/ijtld.20.0278.
9
Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study.间质性肺疾病合并新型冠状病毒肺炎患者死亡几率增加:一项病例对照研究
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1710-1713. doi: 10.1164/rccm.202006-2441LE.
10
Dexamethasone for COVID-19: preliminary findings.地塞米松用于治疗新型冠状病毒肺炎:初步研究结果。
Drug Ther Bull. 2020 Sep;58(9):133. doi: 10.1136/dtb.2020.000045. Epub 2020 Jul 20.

病毒性大流行期间慢性呼吸道疾病的管理:指南与建议简要综述

Management of chronic respiratory diseases during viral pandemics: A concise review of guidance and recommendations.

作者信息

Sharma Prakhar, Mishra Mayank, Dua Ruchi, Saini Lokesh Kumar, Sindhwani Girish

机构信息

Department of Pulmonary, Sleep and Critical Care Medicine, AIIMS Rishikesh, Uttarakhand, India.

出版信息

J Family Med Prim Care. 2022 Nov;11(11):6633-6639. doi: 10.4103/jfmpc.jfmpc_974_21. Epub 2022 Dec 16.

DOI:10.4103/jfmpc.jfmpc_974_21
PMID:36993046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10041299/
Abstract

Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an acute respiratory disease that can lead to respiratory failure and death. Although anticipated that patients with chronic respiratory diseases would be at increased risk of SARS-CoV-2 infection and more severe presentations of COVID-19, it is striking that these diseases appear to be underrepresented in the comorbidities reported for patients with COVID-19. The first wave of COVID-19 has taught us important lessons concerning the enormous burden on the hospitals, shortage of beds, cross infections and transmissions, which we coped together. However, with the subsequent waves of COVID-19 or any other viral pandemic, to ensure that patients with respiratory illnesses receive adequate management for their diseases while minimizing their hospital visits for their own safety. Hence, we prepared an evidence-based summary to manage outpatients and inpatients suspected or diagnosed with COPD, asthma and ILD based on the experience of the first wave of COVID-19 and recommendations by expert societies and organizations.

摘要

2019冠状病毒病(COVID-19)由新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,是一种可导致呼吸衰竭和死亡的急性呼吸道疾病。尽管预计慢性呼吸道疾病患者感染SARS-CoV-2的风险会增加,且COVID-19的表现会更严重,但令人惊讶的是,在报告的COVID-19患者合并症中,这些疾病的比例似乎较低。第一波COVID-19给我们带来了关于医院巨大负担、床位短缺、交叉感染和传播的重要教训,我们共同应对了这些问题。然而,对于随后的COVID-19浪潮或任何其他病毒大流行,为确保呼吸道疾病患者在保证自身安全的同时尽量减少医院就诊次数的情况下,能对其疾病进行充分治疗。因此,我们根据第一波COVID-19的经验以及专家协会和组织的建议,编写了一份循证摘要,以管理疑似或确诊患有慢性阻塞性肺疾病(COPD)、哮喘和间质性肺疾病(ILD)的门诊和住院患者。